著者

堀田 耕平 髙橋 秀徳 本田 裕也 剣持 拓未

出版者

特定非営利活動法人 日本火山学会

雑誌

火山 (ISSN:04534360)

巻号頁・発行日

vol.68, no.2, pp.83-89, 2023-06-30 (Released:2023-07-27)

参考文献数

21

---

Leveling surveys were conducted in Jigokudani valley, Tateyama volcano, since 2015. Subsidence was revealed to have started in 2017‒2018 when a new crater was formed at southwestern area of Jigokudani. Subsidence kept until 2020. During the one-year period from September 2020 to September 2021, ground of Jigokudani was revealed to have re-uplifted. We applied five types of deformation sources (Mogi-type spherical, finite spherical, penny-shaped, rectangular tensile fault and prolate spheroid sources) to the detected deformation. Using the grid search method and the weighted least squares method, we searched the optimal combination of the parameters of each model. Based on the c-AIC value, the penny-shaped deformation source was the best model among them. A penny-shaped inflation source with a radius of 375 m was located including southeastern area of Jigokudani valley where violent fumarole activities have been continued. Its depth was 50 m from the surface. The pressure change in the source of +0.8 MPa yields its volume change of +4800 m3. Inflation of the gas chamber beneath Jigokudani valley might have started due to increase in accumulation of volcanic gas/fluid or decrease in fumarolic activity.

著者

髙橋 秀徳

出版者

行動経済学会

雑誌

行動経済学 (ISSN:21853568)

巻号頁・発行日

vol.11, pp.88-95, 2019-01-22 (Released:2019-01-19)

参考文献数

36

---

本稿は新規株式公開(IPO)の価格形成に関する理論及び実証研究のレビューを行う.IPOパズルについては長い研究の歴史があるが,絶えず新たな研究が発表されている.近年の研究では,テクノロジーの発展に伴い新しい種類のデータや分析手法を利用することで,IPOパズルの解明が進んでいる.本稿では,この分野で特に行動ファイナンスが果たした役割に焦点を当て,IPO研究の過去と未来を俯瞰する.

著者

木村 拓哉 馬場 里英 岡部 太郎 藤井 遼 皆川 裕祐 藤田 健亮 角谷 隆史 加茂 徹郎 高井 千尋 山田 宗 鯉沼 俊貴 萩原 祥弘 三角 香世 小林 孝臣 山中 隆広 髙橋 秀徳 小村 賢祥 荒井 大輔 長尾 元太 小西 駿一郎 神元 繁信 仲地 一郎 小倉 崇以

出版者

一般社団法人 日本感染症学会

雑誌

感染症学雑誌 (ISSN:03875911)

巻号頁・発行日

vol.95, no.2, pp.147-152, 2021-03-20 (Released:2021-10-02)

参考文献数

13

---

A preliminary report from a global study showed that remdesivir, a nucleoside analog pro-drug that was originally developed as a therapeutic drug against Ebola virus, may exert clinical efficacy in cases of COVID-19, by shortening the time to recovery. We had the opportunity to use this new drug in the treatment of 7 COVID-19 patients with respiratory failure.